Citations

Clear

949 citation(s) found for "Li, Bryan".

Abstract 2083: Activated fibroblasts in benign breast tissue are associated with subsequent breast cancer development
Cruz-Reyes, Nicole , Westerman, Pria, Rossi, Matilde , Erak, Camila Pacheco, Mann, Melody Stallings, McCauley, Bryan M. , Sherman, Mark E. , Westerman, Pria, Vierkant, Robert A. , Winham, Stacey J. , Degnim, Amy C. , Radisky, Derek C.

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 2083-2083

10.1158/1538-7445.am2025-2083 Get It

Abstract Introduction: Pseudoangiomatous stromal hyperplasia (PASH) is a benign breast lesion characterized by stromal myofibroblast accumulation. While most women with PASH do not develop breast cancer, a subset eventually does, often in the same breast where PASH was originally diagnosed, even after surgical removal of the lesion. This pattern suggests the presence of a field effect, where alterations in the PASH microenvironment extend beyond the lesion itself, potentially influencing neighboring breast tissue. This study aims to identify specific fibroblasts within PASH-containing tissues that may create a microenvironment conducive to cancer initiation. Methods: We conducted a retrospective analysis of formalin-fixed, paraffin-embedded breast tissue samples from women diagnosed with PASH, comparing those who later developed breast cancer (cases) to those who remained cancer-free (controls). Using transcriptional profiling with NanoString IO360/BC360 panels, multiplex immunofluorescence (MxIF), and spatial transcriptomics via NanoString CosMX SMI, we investigated molecular and histopathological differences. We focused on the expression of fibroblast activation markers (ITGB1, PDGFRβ) and their spatial relationships with proliferating epithelial cells, as well as changes in extracellular matrix (ECM) composition and stiffness. Results: Transcriptional profiling revealed significant upregulation of proliferation-associated genes in epithelial cells from cases. MxIF showed higher Ki-67 levels in epithelial cells from cases, with proliferating cells forming clustered regions. Activated fibroblasts expressing ITGB1 and PDGFRβ were markedly increased in cases and were located closer to proliferating epithelial cells. Spatial transcriptomics uncovered gene expression changes in fibroblasts indicative of an activated phenotype, and in epithelial cells, consistent with responses to increased tissue stiffness and mechanotransduction signaling. Polarized light imaging with picrosirius red staining revealed enhanced collagen cross-linking and thick fibril formation in cases, indicating greater ECM stiffness. Conclusions: Our findings suggest that a subset of activated fibroblasts in benign breast tissue creates a pro-tumorigenic microenvironment through ECM remodeling and increased tissue stiffness, promoting epithelial proliferation and potentially driving cancer development. The spatial proximity of these fibroblasts to proliferating epithelial cells underscores their possible role in early carcinogenesis. This study introduces the novel concept of cancer-predisposing fibroblasts in benign breast tissue, providing new insights into microenvironmental changes that precede cancer and offering potential targets for early detection and intervention. Citation Format: Nicole Cruz-Reyes, Pria Westerman, Matilde Rossi, Camila Pacheco Erak, Melody Stallings Mann, Bryan McCauley, Robert Vierkant, Stacey Winham, Mark Sherman, Amy Degnim, Derek Radisky. Activated fibroblasts in benign breast tissue are associated with subsequent breast cancer development [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2083.
Abstract 6266: Spatial profiling of prognostic differences in the tumor microenvironment between primary and metastatic ovarian cancer using multiplexed protein imaging
Moore, Raymond M. , Atherton, Chathu L., Block, Matthew S. , McCauley, Bryan M. , Goode, Ellen L., Guo, Ray, Huang, Yajue, Wang, Chen , Novotny, Brenna C. , Winham, Stacey J. , Markovic, Svetomir N.

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 6266-6266

10.1158/1538-7445.am2025-6266 Get It

Abstract Background: The tumor microenvironment (TME) plays a pivotal role in ovarian cancer (OC) progression and prognosis, while also contributing to biological differences between primary and metastatic tumors. This study examines OC TMEs to uncover associations with clinical prognosis and tumor biology by analyzing paired primary and metastatic tumors from the same patients. Methods: This study focused on 57 stage-IIIC/IV OC patients treated at the Mayo Clinic, all of whom underwent surgical debulking and adjuvant therapies. All patients provided informed consent, and the study received IRB approval. A tissue microarray (TMA) was specifically designed and constructed, containing paired primary and metastatic tissue cores from the same patients. 147 tissue cores from the constructed TMA were profiled using a 35-antibody panel, with 17 antibodies for cell phenotyping and 18 for functional state characterization. Profiling was performed using Cell DIVE, a multiplexed imaging solution at the single-cell level developed by Leica Microsystems. After cell segmentations and classifications, detailed spatial niche and regional analyses were performed at the single-cell level. Immune cell populations, as well as their TME distributions, were characterized to conduct prognostic associations and contrast primary and metastasis differences. Results: A total of 1,292,988 total cells (after excluding low-density signals and ambiguous classifications) were analyzed, with a median of 8,033 cells per core. Using spatial neighborhood analysis, 12 distinct spatial niches were identified with specific cell types and/or unique functional states. Among these, a macrophage- and fibroblast-enriched niche at the tumor-stroma interface was associated with improved overall survival (p=0.008). Another rare Treg-enriched niche, along with other immune cells, demonstrated protective effects, particularly in patients with residual macroscopic tumors after debulking surgery (p=0.05), while no significant effects were observed in those without visible residual disease (p=0.8). When comparing primary and metastatic tumors, metastatic lesions exhibited significantly increased tumor mass (p=2e-4) and a notable reduction in helper T cells (p=0.04) in tumor areas, as well as significantly increased fibroblast cells in tumor-stroma interfacing regions (p=0.002), reflecting distinct immunosuppressive and tumor-promoting shifts. Conclusion: This study reveals spatial and cellular differences in primary and metastatic OC TMEs, distribution differences linked to prognosis and surgical outcomes. These findings emphasize the potential of spatially resolved TME profiling to refine adjuvant and neoadjuvant therapeutic strategies. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 6266.
Abstract 2077: Elevated PI16 expression in fibroadenoma fibroblasts is associated with subsequent breast cancer development
Westerman, Pria, Cruz-Reyes, Nicole , Erak, Camila Pacheco, McCauley, Bryan M. , Sherman, Mark E. , Westerman, Pria, Vierkant, Robert A. , Winham, Stacey J. , Degnim, Amy C. , Radisky, Derek C.

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 2077-2077

10.1158/1538-7445.am2025-2077 Get It

Abstract Introduction: Fibroadenoma is the most common type of benign breast lesion and is not traditionally considered an indicator of increased breast cancer risk. This study aimed to identify biomarkers within fibroadenoma associated with subsequent breast cancer development using patient samples from the Mayo Clinic Benign Breast Disease (BBD) cohort. Methods: We analyzed formalin-fixed paraffin-embedded (FFPE) breast biopsy samples from patients diagnosed with non-proliferative fibroadenoma who either developed breast cancer later (n=10) or remained cancer-free (n=5). NanoString RNA profiling identified differentially expressed genes in fibroblasts associated with subsequent cancer development. Immunohistochemistry was first done to compare overall expression of PI16 in this cohort. Opal multiplex immunofluorescence staining (mIF) was then performed to evaluate the expression of PI16 in fibroblasts (Vim+PanCK-) and assess immune cell infiltration (CD45+) in different tissue compartments. Fibroblasts were identified by vimentin positivity (Vim+), and epithelial cells were marked by pan-cytokeratin positivity (PanCK+). Results: Compared to patients who remained cancer-free, those who developed breast cancer showed significantly increased expression of PI16 in fibroblasts (PI16+Vim+PanCK-, 3.25-fold increase, p=0.0011). Additionally, the number of immune cells (CD45+) was significantly decreased (0.52-fold, p=0.03) in the fibroadenoma lesions of patients who later developed cancer. Conclusions: Our findings suggest that elevated expression of PI16 in fibroblasts within fibroadenoma may serve as potential biomarkers for predicting breast cancer risk for women with fibroadenoma. PI16 encodes Peptidase Inhibitor 16, which is implicated in modulating fibroblast activity and extracellular matrix remodeling—processes that can contribute to a tumor-supportive microenvironment. Elevated levels of this protein in fibroblasts suggest an altered microenvironment that may foster tumor initiation and progression. The decreased immune cell infiltration further implies an immunosuppressive microenvironment that may facilitate cancer progression. As these markers can be detected in FFPE samples, our results could lead to the development of a readily applicable clinical test to identify fibroadenoma patients at increased risk for breast cancer, enabling earlier intervention and surveillance. Citation Format: Pria Westerman, Nicole Cruz-Reyes, Camila Pacheco Erak, Robert Vierkant, Bryan McCauley, Stacey Winham, Mark Sherman, Amy Degnim, Derek Radisky. Elevated PI16 expression in fibroadenoma fibroblasts is associated with subsequent breast cancer development. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 2077.
Abstract 1912: Immune and molecular markers in benign breast disease predict risk of node-positive breast cancer
Rossi, Matilde , Cruz-Reyes, Nicole , Navarro, Trista, McCauley, Bryan M. , Stallings‐Mann, Melody , Vierkant, Robert A. , Winham, Stacey J. , Sherman, Mark E. , Degnim, Amy C. , Radisky, Derek C.

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 1912-1912

10.1158/1538-7445.am2025-1912 Get It

Abstract Background: Breast cancer (BC) remains a leading health concern worldwide and is often undetected until it metastasizes, limiting treatment options and worsening prognosis. Early detection of molecular and immune markers in benign breast disease (BBD) could identify women at elevated risk of developing invasive, node-positive BC, enabling targeted surveillance and prevention efforts. Building on this premise, we investigated the immune and molecular landscape of BBD biopsies preceding BC development to enhance risk stratification and inform preventive strategies. Methods: Utilizing the Mayo Clinic BBD cohort, we conducted a case-control study comparing women who developed node-positive BC following their BBD biopsy (cases; n=8) to those who remained cancer-free (controls; n=11), matched on patient age and biopsy date. Differential gene expression was assessed using the NanoString nCounter system to identify differentially expressed genes between cases and controls. We developed a multiplex immunofluorescence (MxIF) approach using the Opal system by Akoya Biosciences for comprehensive marker detection in formalin-fixed, paraffin-embedded (FFPE) tissue samples. Digitized images were segmented for cell phenotyping, and spatial relationships of immune cells were analyzed and compared between cases and controls. Results: Our findings revealed significantly increased expression levels of immunosuppressive genes in the case group, including CD48, CD84, IL-32, and LAIR1. Immunohistochemical analyses showed that controls exhibited higher frequencies of CD68+ (macrophages), CD11c+ (M1 macrophages), and CD206+ (M2 macrophages) cells compared to cases. Notably, controls had a significant increase in CD68+CD11c+ cells, indicative of a pro-inflammatory, antitumorigenic M1 macrophage polarization. Furthermore, our MxIF analyses provided novel insights into spatial biomarker localization, enhancing prognostic accuracy. Conclusions: The decreased numbers of immune cells and increased expression of immunosuppressive genes in BBD biopsies may be associated with an elevated risk of developing axillary node-positive BC. These findings emphasize the importance of dissecting molecular and immune interactions in BBD for risk assessment. Our results have the potential to improve individualized risk stratification, leading to more targeted surveillance and informed screening. This research not only contributes to our understanding of BC pathogenesis but also opens avenues for developing novel preventive strategies, potentially reducing BC incidence and mortality through early intervention. Citation Format: Matilde Rossi, Nicole Cruz-Reyes, Trista Navarro, Melody L. Stallings-Mann, Bryan M. McCauley, Robert A. Vierkant, Stacey J. Winham, Mark E. Sherman, Amy C. Degnim, Derek C. Radisky. Immune and molecular markers in benign breast disease predict risk of node-positive breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 1912.
Abstract MP24: Socioeconomic Disparities in Cardiac Rehabilitation Perceptions and Delivery Mode Preferences: A Nationally Representative Survey Among Diverse Cardiac Patients.
Anyetei-Anum, Grace Patrice, Averkamp, Natalie , Johnson, Matthew P. , Krogman, Ashton , Clark, Donald , Echols, Melvin , Hall, Michael E. , Hodgman, Karen, Kaihoi, Brian, Kopecky, Stephen L. , Leth, Shawn , Malik, Shaista , Scales, Robert , Shultz, Adam M. , Schulte, Phillip J. , Olson, Thomas P. , Abraham, Helayna , Marsteller, Jill , Mathews, Lena , Taylor, Bryan J. , Thomas, Randal J. , Wong, Nathan D. , Brewer, LaPrincess C.

Mayo Clinic

Circulation | April 17, 2025 | Volume: 151 | Issue: Suppl_1 | Pages: No page available

10.1161/cir.151.suppl_1.mp24 Get It

Background: Cardiac rehabilitation (CR) is essential to secondary cardiovascular disease prevention and management of cardiac patients. Despite its proven benefits, CR remains underutilized with enrollment and completion rates ranging from 10-30% in the US. Yet, there is a scarcity of nationally representative data among diverse populations on socioeconomic differences in barriers and beliefs of CR participation and delivery mode preferences. Hypothesis: The perceptions (barriers, beliefs), CR delivery mode preferences, and CR utilization (prior enrollment) varies by socioeconomic status (SES) among CR-eligible individuals. Methods: We conducted an anonymous national electronic survey from March 2023 to January 2024 of individuals self-reporting a prior CR-eligible diagnosis. The 22-item CR Barriers Scale assessed perceived barriers to CR enrollment and participation using a 5-point Likert scale (strongly disagree to strongly agree). A 13-item, validated questionnaire assessed 4 subscales pertaining to patients’ beliefs about CR, each rated on a 5-point Likert scale (strongly disagree to strongly agree): perceived necessity, concerns about exercise, practical barriers and perceived suitability. CR delivery mode preferences were ascertained (eg, virtual, at-home, etc.). Mean barriers and belief scores as well as delivery mode preferences were stratified by SES. Low SES was defined as ≤ high school education, Medicaid insurance, or uninsured. High SES was defined as > high school education and non-Medicaid health insurance. Responses were analyzed using descriptive statistics with R software. Results: A total of 466 participants completed the survey (38.1% women, 30.6% minoritized racial/ethnic group, 29.6% low SES, 95% response rate) ( Table 1 ). The majority indicated prior enrollment in CR (81.5%) with no difference by SES. CR barrier scores did not differ significantly by SES (p=0.331) ( Table 2 ). Beliefs about CR perceived necessity and perceived suitability differed by SES (p<0.001 and p=0.025), but beliefs regarding concerns about exercise and practical barriers did not. The low SES group reported a higher preference for completely at-home CR compared to the high SES group (33.6% vs 7.4%, p<0.001). Conclusion: Our findings suggest that CR beliefs varied by SES while utilization did not. For CR-eligible patients experiencing socioeconomic disadvantage, at-home CR may be a preferred alternative to center-based CR to increase CR participation and adherence.
Tremor and Disability Outcomes After Deep Brain Stimulation for Multiple Sclerosis-associated Tremor (P12-1.014)
Permezel, Fiona , Jackson, Lauren , Kantarci, Orhun H. , Keegan, Mark , Pittock, Sean J, Miller, Kai J. , Klassen, Bryan T. , Banks, Samantha A. , Baker, Matthew , Flanagan, Eoin P. , Tobin, W. Oliver , Pittock, Sean J.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000210835 Get It

Capturing What Matters: Patient Reported LGI1-ANTibody Encephalitis Outcome RatiNg Scale (LANTERN) (P9-8.006)
Ceronie, Bryan , Strippel, Christine , Soltys, John , Kelly, Mark , Wagner, Barbara J. , Lin, Ann , Handel, Adam E. , Binks, Sophie , Irani, Sarosh R. , Powell, Philip A.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000210640 Get It

Clinical Utility of Skin Biopsy for Cutaneous Phosphorylated Alpha-synuclein in Cognitive Manifestations of Lewy Body Disease (P1-3.012)
Rigby, Michael , Barnard, Leland R , Trottier, Zachary, Neth, Bryan J. , Savica, Rodolfo , Miyagawa, Toji , Knopman, David S. , Petersen, Ronald C. , Graff‐Radford, Jonathan , Neth, Byran J. , Botha, Hugo , Switzer, Aaron , Ramanan, Vijay K. , Jones, David T. , Louis, Erik K. St. , Knopman, David S. , Boeve, Bradley F. , McCarter, Stuart J.

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000211869 Get It

Increased Cerebral Blood Flow in Cognitively Intact APOE4 Carriers Predicts Cerebral Amyloid Burden (P4-3.003)
Dumitrașcu, Oana , Woodruff, Bryan K. , Zhou, Yuxiang, Caselli, Richard J. , Nikolova, Simona , Dumkrieger, Gina , Baxter, Leslie C. , Zhou, Yuxiang

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000210596 Get It

Alzheimer’s Disease Neuropathologic Change in Cognitively Impaired Prostate Cancer Survivors (P1-6.008)
Neth, Bryan J. , Alden, Eva , Ghaffar, Umar , Petersen, Ronald C. , Ruddy, Kathryn J. , Karnes, Jeffrey , Graff‐Radford, Jonathan , Neth, Byran J. , Nguyen, Aivi T. , Raghunathan, Aditya , Botha, Hugo , Ramanan, Vijay K. , Jack, Clifford R. , Knopman, David S. , Childs, Daniel S. , Wefel, Jeffrey S. , Vemuri, Prashanthi

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000212210 Get It